BioSpace News Archive

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced that it has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for ATI-1777, an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, for the treatment of moderate to severe atopic dermatitis (AD).

New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or “liquid biopsies.”

GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary financial and operational results for the quarter ended June 30, 2020.

Sandoz Inc. today announced it has entered into a long-term agreement with Civica Rx (Civica, Inc.) to manufacture and supply critical injectable generic medicines, to help reduce supply shortages and ensure acute care settings can deliver optimal patient car

Tower Health and Drexel University, which in partnership own and operate St. Christopher’s Hospital for Children, announced that Donald Mueller will become the new Chief Executive Officer for St. Christopher’s, effective July 27, 2020.

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob Goeltz will join Arcus as Chief Financial Officer on August 1, 2020

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2020 results after the financial markets close on Thursday, July 30, 2020.

Owens & Minor, Inc. announced the final results and expiration of its previously announced offers to purchase for cash up to a maximum aggregate purchase price, excluding accrued interest, equal to $240 million of the Company’s 3.875% senior notes due 2021 and 4.375% senior notes due 2024 and related consent solicitation, upon the terms and conditions described in the Company’s Offer to Purchase and Consent Solicitation Statement dated June 5, 2020.

With hiring and growth happening at dozens of scientific, manufacturing and biotech companies in the Pacific Northwest, the Oregon Bioscience Association has retooled its myriad educational workforce training, classes and workshops to now be offered online live with industry-expert instructors, through its well-known BioPro program.